Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Why is Methanex stock climbing today?

Why is Methanex stock climbing today?

Methanex stock experienced a 2.5% increase, trading at CA$85.39, despite a generally negative performance across North American markets. The company's decision to partially redeem its US$300 million in senior notes, due in October 2027, was well-received by investors. This move highlighted Methanex's robust cash flow position and its dedication to lowering leverage.

CEO Rich Sumner explained that the debt action was in line with the company's balance sheet objectives, stemming from tight global methanol market conditions and the company's strengthened production capabilities. The positive sentiment was further bolstered by UBS maintaining a Buy rating on the stock and raising its price target.

Q2 2026 results showcased record North American production and strong EBITDA performance, fueled by higher methanol prices due to Middle East supply issues. Additionally, Methanex is set to pay a quarterly dividend of US$0.185 per share on September 30, potentially attracting income-seeking investors. Although North American markets were underperforming, Methanex's upward movement demonstrated stock-specific strength rather than following a broader market trend.

Compared to the S&P/TSX Composite, Methanex outperformed the weak market session, emphasizing its commodity-driven nature. The positive outcome of the debt redemption, a supportive methanol supply outlook, a continued positive outlook from analysts, and an upcoming dividend payment all contributed to the stock's rise today. At present, Methanex's shares are trading above its 52-week low of CA$45.01, while still below its 52-week high of CA$92.97, indicating potential for further recovery as the market anticipates upcoming Q3 results.

Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at investing.com →

More in Finance & Markets

Poisons board sounds alarm after fake lucentis eye injection is found in Kenyan market

Kenya’s Pharmacy and Poisons Board (PPB) has issued an urgent public alert after detecting falsified Lucentis (Ranibizumab) 0.3 mg eye injections circulating in the Kenyan market, warning that the…

  • Kenya Pharmacy and Poisons Board warns about fake Lucentis eye injections
  • Counterfeit medicine labeled as Genentech product found in market
  • One arrested, more legal action expected against counterfeiters

More from Monday 28 September →